Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
出版年份 2023 全文链接
标题
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
作者
关键词
-
出版物
Current Pain and Headache Reports
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-24
DOI
10.1007/s11916-023-01183-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Serum Alpha and Beta‐CGRP Levels in Chronic Migraine Patients Before and After Monoclonal Antibodies Against CGRP or its Receptor
- (2023) Gabriel Gárate et al. ANNALS OF NEUROLOGY
- Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
- (2023) Katharina Kaltseis et al. BMC Neurology
- Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study
- (2023) Luigi Francesco Iannone et al. CEPHALALGIA
- Real-world treatment satisfaction with erenumab in migraine: analysis of the US National Health and Wellness Survey
- (2023) Purnima Pathak et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
- (2023) Andreas A. Argyriou et al. EUROPEAN JOURNAL OF NEUROLOGY
- An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
- (2023) Francesca Schiano di Cola et al. EUROPEAN JOURNAL OF NEUROLOGY
- Headache in patients with inflammatory bowel disease: Migraine prevalence according to the Migraine Screening-Questionnaire (MS-Q) and headache characteristics
- (2023) Alicia Gonzalez-Martinez et al. Gastroenterologia y Hepatologia
- Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study
- (2023) Hyoung Cheol Lee et al. NEUROLOGICAL SCIENCES
- Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
- (2023) Lucas Hendrik Overeem et al. Frontiers in Neurology
- Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan
- (2023) Shiho Suzuki et al. Frontiers in Neurology
- A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
- (2023) Ja Bin Hong et al. Pharmaceuticals
- Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score
- (2022) Luigi Francesco Iannone et al. CNS DRUGS
- Predictors of sustained response and effects of the discontinuation of anti‐calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine
- (2022) Luigi Francesco Iannone et al. EUROPEAN JOURNAL OF NEUROLOGY
- Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
- (2022) Simona Guerzoni et al. NEUROLOGICAL SCIENCES
- Trigeminal sensory modulatory effects of galcanezumab and clinical response prediction
- (2022) Kuan-Po Peng et al. PAIN
- Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
- (2022) Soonwook Kwon et al. CEPHALALGIA
- Sex Differences in Chronic Migraine: Focusing on Clinical Features, Pathophysiology, and Treatments
- (2022) Chia-Kuang Tsai et al. Current Pain and Headache Reports
- CGRP Targeting Therapy for Chronic Migraine—Evidence from Clinical Trials and Real-world Studies
- (2022) Yen-Feng Wang et al. Current Pain and Headache Reports
- Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
- (2022) Modar Khalil et al. EUROPEAN JOURNAL OF NEUROLOGY
- Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study
- (2022) Hannah Schenk et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
- (2022) Maurice T. Driessen et al. JOURNAL OF HEADACHE AND PAIN
- Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
- (2022) Hauke Basedau et al. eLife
- Cerebral Blood Flow and Other Predictors of Responsiveness to Erenumab and Fremanezumab in Migraine—A Real-Life Study
- (2022) Magdalena Nowaczewska et al. Frontiers in Neurology
- Salivary CGRP and erenumab treatment response: towards precision medicine in migraine
- (2022) Alicia Alpuente et al. ANNALS OF NEUROLOGY
- Machine‐learning‐based approach for predicting response to anti‐calcitonin gene‐related peptide ( CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study
- (2022) Alicia Gonzalez‐Martinez et al. EUROPEAN JOURNAL OF NEUROLOGY
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
- (2022) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation
- (2022) Michael Lowe et al. JOURNAL OF HEADACHE AND PAIN
- Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study
- (2022) Ilaria Cetta et al. NEUROLOGICAL SCIENCES
- Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
- (2022) Ann M. Murray et al. Current Pain and Headache Reports
- Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
- (2022) Piero Barbanti et al. JOURNAL OF HEADACHE AND PAIN
- Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
- (2022) Tsubasa Takizawa et al. BMC Neurology
- Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab
- (2022) Todd J. Schwedt et al. JOURNAL OF HEADACHE AND PAIN
- Association between response to triptans and response to erenumab: real-life data
- (2021) Ilaria Frattale et al. JOURNAL OF HEADACHE AND PAIN
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study
- (2021) Marta Torres-Ferrús et al. JOURNAL OF NEUROLOGY
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
- (2021) Robert Belvís et al. JOURNAL OF HEADACHE AND PAIN
- Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache
- (2021) Umberto Pensato et al. NEUROLOGICAL SCIENCES
- Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series
- (2021) María Del Pilar Briceño-Casado et al. European Journal of Hospital Pharmacy-Science and Practice
- Predictors of response to erenumab after 12 months of treatment
- (2021) Carlo Baraldi et al. Brain and Behavior
- Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
- (2021) Fabrizio Vernieri et al. EUROPEAN JOURNAL OF NEUROLOGY
- Clinic and genetic predictors in response to erenumab
- (2021) Chiara Zecca et al. EUROPEAN JOURNAL OF NEUROLOGY
- Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
- (2021) Edoardo Caronna et al. JOURNAL OF HEADACHE AND PAIN
- Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
- (2021) Jean Schoenen et al. Frontiers in Neurology
- PEARL study protocol: a real-world study of fremanezumab effectiveness in patients with chronic or episodic migraine
- (2021) Messoud Ashina et al. Pain Management
- Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting
- (2020) Anne-Sophie Wattiez et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Gut-brain Axis and migraine headache: a comprehensive review
- (2020) Mahsa Arzani et al. JOURNAL OF HEADACHE AND PAIN
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study
- (2020) Piero Barbanti et al. HEADACHE
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review
- (2019) Ivan Urits et al. Current Pain and Headache Reports
- Response to BotulinumtoxinA in a migraine cohort with multiple comorbidities and widespread pain
- (2019) Meredith Barad et al. REGIONAL ANESTHESIA AND PAIN MEDICINE
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adherence to oral migraine-preventive medications among patients with chronic migraine
- (2014) Zsolt Hepp et al. CEPHALALGIA
- Calcitonin gene-related peptide: A molecular link between obesity and migraine?
- (2010) A. Recober et al. DRUG NEWS & PERSPECTIVES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search